Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
1985-5-1
|
pubmed:abstractText |
Twenty patients bearing advanced colorectal carcinoma, confirmed by histology, were evaluated after undergoing a sequential chemotherapeutic schedule which consisted of methotrexate, 200 mg/m2 in intravenous infusion during 4 h followed 1 h later by 5-fluorouracil, 600 mg/m2 in intravenous bolus. Twenty hours after ending the MTX administration, leucovorine, 14 mg/m2, was given intramuscularly every 6 h, in 8 doses. Courses were repeated every 15 days. Of 20 patients, 3 bearing colon carcinoma, without previous radiotherapy or chemotherapy, had a partial response. No change was registered in 6 cases. There was no significant difference in the survival of responders, those with stable illness and those with progression. Results were no better than those obtained with 5-fluorouracil used as a single drug and are in agreement with studies that established a 1-h interval between the administration of both drugs.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0300-8916
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
31
|
pubmed:volume |
70
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
549-53
|
pubmed:dateRevised |
2008-12-12
|
pubmed:meshHeading |
pubmed-meshheading:6531797-Adult,
pubmed-meshheading:6531797-Aged,
pubmed-meshheading:6531797-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:6531797-Colonic Neoplasms,
pubmed-meshheading:6531797-Drug Administration Schedule,
pubmed-meshheading:6531797-Female,
pubmed-meshheading:6531797-Fluorouracil,
pubmed-meshheading:6531797-Humans,
pubmed-meshheading:6531797-Male,
pubmed-meshheading:6531797-Methotrexate,
pubmed-meshheading:6531797-Middle Aged,
pubmed-meshheading:6531797-Rectal Neoplasms
|
pubmed:year |
1984
|
pubmed:articleTitle |
Sequential combination chemotherapy with methotrexate and 5-fluorouracil in advanced colorectal carcinoma.
|
pubmed:publicationType |
Journal Article
|